• Vitrolife’s third-quarter 2026 net sales rose 6% to SEK 884 million.
• EBITDA reached SEK 279 million, with the margin widening to 31.6% from 30.3%.
• Net income increased to SEK 124 million from SEK 102 million; earnings per share reached SEK 0.94.
• Operating cash flow fell to SEK 224 million from SEK 255 million, mainly reflecting weaker working capital contributions.
• Restructuring delivered SEK 20 million in quarterly savings, with gross headcount reduced by 8%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitrolife AB published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.